Shionogi-ViiV Healthcare LLC Presents Positive Data
on Investigational Once-Daily Integrase Inhibitor at
International AIDS Conference
Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 Study
Antiviral activity shown by S/GSK1349572 in treatment-experienced subjects resistant to raltegravir from VIKING Study
Vienna, Austria, July 22, 2010 – Shionogi-ViiV Healthcare LLC today reported data from two
Phase IIb studies showing that its once-daily, unboosted investigational integrase inhibitor,
S/GSK1349572 (‘572), exhibited potent antiviral activity in treatment-naïve HIV subjects as well
as in treatment-experienced subjects resistant to raltegravir (RAL). These clinical results and
additional findings on the virologic profile of ‘572 were presented at the XVIII International AIDS
Conference in Vienna, Austria. ‘572 is the only once-daily, unboosted integrase inhibitor in Phase
IIb clinical development.
“There remains a significant need for additional medicines that can help address the complex
treatment issues for HIV, and also help simplify treatment regimens for patients. As a once-daily,
unboosted integrase inhibitor, ‘572 could provide an important therapy for patients living with
HIV,” stated Dr. John Pottage, Chief Scientific and Medical Officer of ViiV Healthcare. “We look
forward to confirming the safety and efficacy of this compound in Phase III studies, which are
expected to begin by the end of the year.”
"We are very pleased with the progress of '572 in collaboration with ViiV Healthcare. We look
forward to completing the clinical development process with '572 and providing benefit to the
millions of HIV-infected patients throughout the world," said Dr. Tsutae "Den" Nagata, Chief
Medical Officer, Shionogi & Co., Ltd.
Overall, five abstracts were presented during the conference relating to the integrase inhibitor
program which is being developed by Shionogi-ViiV Healthcare. Highlights from presentations on
‘572 are described below.
SPRING-1 Study Data (Abstract Number THLBB205)
SPRING-1 is an ongoing Phase IIb, multicenter, partially-blinded, dose-ranging study comparing
‘572 to efavirenz (EFV) in 205 treatment-naïve subjects. Individuals were randomized 1:1:1:1 to
10 mg, 25 mg or 50 mg of ‘572 or EFV 600mg once daily in combination with either
tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC). Eighty-six percent of
subjects were male, 20 percent were non-white and 26 percent had HIV-1 RNA levels 100,000
copies/mL.
Key SPRING-1 results through 16 weeks included the following:
– At Week 16, more than 90 percent of subjects treated with ‘572 achieved viral suppression
(HIV-1 RNA levels 50 copies/mL) compared to 60 percent of subjects treated with EFV. The
percentage of subjects who achieved viral suppression was 96 percent, 92 percent and 90
percent for the 10 mg, 25 mg and 50 mg ‘572 doses, respectively.
– Time to viral suppression was significantly shorter for subjects treated with ‘572 compared to
EFV (p 0.001). By Week 4, 66 percent of subjects treated with ‘572 were suppressed,
compared to 18 percent of subjects treated with EFV.
– Two virologic failures occurred, one in the ‘572 treatment group and one in the EFV treatment
group. No integrase-associated substitutions in genotype or changes in INI susceptibility (to
either ‘572 or RAL) were observed in the subject receiving ‘572 with virologic failure.
– ‘572 was generally well tolerated. Drug-related adverse events of moderate or higher
intensity were reported in more subjects receiving EFV (9/50, 18 percent of subjects) than
‘572 (9/155, 6 percent of subjects). No drug-related moderate to severe adverse event
occurred in more than one subject receiving ‘572. The most frequent category of these events
in the EFV and ‘572 arms were gastrointestinal (4 percent versus 2 percent, respectively),
which were the only events that occurred in 1 subject receiving ‘572. Other events occurring
in 1 subject treated with EFV were psychiatric (6 percent) and rash (4 percent) disorders. No
dose-relationship for adverse events was noted across ‘572 doses. More subjects receiving
EFV (n=4, 8 percent) withdrew from treatment due to adverse events compared to ‘572 (n=1,
1 percent).
VIKING Study Data (Abstract Number MOAB0105)
The VIKING study is an ongoing Phase IIb multicenter, open-label, single arm study designed to
assess the antiviral activity, safety and tolerability of ‘572, as short-term functional monotherapy
and over a 24-week treatment period with optimized background therapy in treatment-
experienced, HIV-infected adult subjects with RAL resistance. Genotypic and phenotypic changes
in HIV integrase were also evaluated.
The study enrolled 27 subjects with screening plasma HIV-1 RNA ≥1000c/mL showing genotypic
resistance to RAL and at least two other antiretroviral classes. All subjects had RAL-associated
mutations at screening. Subjects received ‘572 50mg QD while continuing their failing regimen
(without RAL) to Day 11 when the background regimen was optimized, where feasible, and ‘572
continued.
Key VIKING study results through Day 11 included the following:
– The majority of subjects treated with ‘572 demonstrated positive antiviral response, as
measured by plasma HIV-1 RNA 400 c/mL or decline of 0.7 log10, despite the high level
resistance to RAL.
– Viral response differed according to baseline integrase inhibitor genotype. Responders
included all 16 subjects with N155H, Y143H or Q148 single mutant pathways, three of four
subjects with Q148 plus one secondary mutation and two subjects with other mutations.
None of the subjects with Q148 plus two or more secondary mutations showed antiviral
response.
– ‘572 was generally well tolerated. The most frequent adverse events were diarrhoea (N = 3)
and insomnia (N = 3).
– Few integrase genotypic changes were observed, and minimal changes in ‘572 susceptibility
were observed, suggesting minimal virus evolution over the 11-day observation period. On
Day 1, 25 of 27 subjects had virus with RAL-associated signature mutations. By Day 11, of 18
subjects with evaluable virus, 17 had phenotypic susceptibility changes to ‘572 2-fold. The
additional paired viral isolate had a susceptibility change of ~6-fold.
Additional Data on ‘572 (Abstract Number MOPE0032)
Additional data presented supported the potency of ‘572 when tested against a broad panel of
HIV isolates in peripheral blood mononuclear cells and monocyte-derived-macrophages
independent of HIV subtype. These observations further support clinical development of ‘572
across all HIV-1 subtypes.
Further study is necessary to determine conclusively the efficacy, safety, and resistance profile of
‘572.
About Shionogi-ViiV Healthcare LLC
‘572 is the lead compound in Shionogi-ViiV Healthcare LLC. It is currently the only once-daily,
unboosted integrase inhibitor in Phase IIb clinical development. Shionogi-ViiV Healthcare LLC is
also developing second-generation integrase inhibitors, including S/GSK1265744, currently in
Phase II development.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (NYSE: GSK)
and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living
with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has
done before and take a new approach to deliver effective and new HIV medicines as well as
support communities affected by HIV. For more information on the company, its management,
portfolio, pipeline and commitment, please visit
www.viivhealthcare.com.
About Shionogi & Co., Ltd
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical
company dedicated to placing the highest value on patients. Shionogi’s Research and
Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic
Syndrome. The Company is the originator of innovative medicines which have been successfully
delivered to millions of patients worldwide. In addition, Shionogi is engaged in new research
areas such as allergy and cancer. Contributing to the health of patients around the world through
development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit
www.shionogi.co.jp
. For more information on Shionogi Inc. headquartered in Florham Park, NJ,
please visit
www.shionogi-inc.com
. Enquiries:
UK Media enquiries:
Rebecca Hunt
Claire Brough
(020) 8380 6275
(020) 8047 5502
US Media enquiries:
Marc Meachem
(919) 483 5005
GSK European Analyst/Investor enquiries:
David Mawdsley
(020) 8047 5564
Sally Ferguson
(020) 8047 5543
Gary Davies
(020) 8047 5503
GSK US Analyst/ Investor enquiries:
Tom Curry
(215) 751 5419
Jen Hill Baxter
(215) 751 7002
Shionogi & Co., Ltd. enquiries
Corporate
Communications
+81 6 6209 7885
